Treatment with Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, Decreases Serum Cholesterol in Patients with Lung Cancer
10.7570/kjo.2016.25.4.233
- Author:
Yea Eun KANG
1
;
Ji Min KIM
;
Kyong Hye JOUNG
;
Hyun Jin KIM
;
Bon Jeong KU
Author Information
1. Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. bonjeong@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Gefitinib;
Cholesterol;
Lung neoplasm
- MeSH:
Animals;
Blood Glucose;
Body Mass Index;
Cholesterol;
Epidermal Growth Factor;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hypercholesterolemia;
Insulin Resistance;
Lung Neoplasms;
Lung;
Medical Records;
Metabolism;
Mice;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor;
Retrospective Studies;
Triglycerides
- From:Korean Journal of Obesity
2016;25(4):233-239
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Statins are used to treat hypercholesterolemia; however, major cardiovascular events are decreased only 30% by statin treatment. Treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been reported to decrease serum glucose levels and improved insulin sensitivity in mice and humans, but there was no study in serum cholesterol levels. This study examined the effect of gefitinib, an EGFR tyrosine kinase inhibitor, on cholesterol metabolism in humans. METHODS: We retrospectively reviewed the medical records of 299 patients with primary lung cancer treated with gefitinib for ≥1 month and 72 patients with other treatments. Serum cholesterol, serum triglycerides, and body mass index were measured before and after treatment. The changes in serum cholesterol, serum triglycerides, and body mass index were compared between the gefitinib treatment group and the control group and were also analyzed according to the presence or absence of EGFR mutations. RESULTS: Serum cholesterol levels decreased significantly from 178.9 to 164.4 mg/dL after 1-month of gefitinib treatment. A total of 54 of the 299 patients underwent examination for the presence of the EGFR mutations. Serum cholesterol was significantly decreased in the group with the activating EGFR mutation (Δ=21.3 mg/dL) compared to that of those without the EGFR mutation (Δ=-3.1 mg/dL) after treatment with gefitinib. In contrast, there was no significantly difference between the two groups in control patients. CONCLUSION: Treatment with gefitinib decreased serum cholesterol in lung cancer patients, particularly in those with activating mutations in EGFR. These data suggest that EGFR tyrosine kinase inhibitors provide a novel and attractive strategy for the treatment of hypercholesterolemia.
